Application of a Scalable Plant Transient Gene Expression Platform for Malaria Vaccine Development by Holger Spiegel et al.
ORIGINAL RESEARCH
published: 23 December 2015
doi: 10.3389/fpls.2015.01169
Frontiers in Plant Science | www.frontiersin.org 1 December 2015 | Volume 6 | Article 1169
Edited by:
Edward Rybicki,
University of Cape Town, South Africa
Reviewed by:
George Peter Lomonossoff,
John Innes Centre, UK
Udo Conrad,
Leibniz-Institut Für Pflanzengenetik
Und Kulturpflanzenforschung (IPK),
Germany
John D. Hamill,
Deakin University, Australia
*Correspondence:
Alexander Boes
alexander.boes@ime.fraunhofer.de
†
Shared first author.
Specialty section:
This article was submitted to
Plant Biotechnology,
a section of the journal
Frontiers in Plant Science
Received: 02 October 2015
Accepted: 07 December 2015
Published: 23 December 2015
Citation:
Spiegel H, Boes A, Voepel N, Beiss V,
Edgue G, Rademacher T, Sack M,
Schillberg S, Reimann A and Fischer R
(2015) Application of a Scalable Plant
Transient Gene Expression Platform
for Malaria Vaccine Development.
Front. Plant Sci. 6:1169.
doi: 10.3389/fpls.2015.01169
Application of a Scalable Plant
Transient Gene Expression Platform
for Malaria Vaccine Development
Holger Spiegel 1†, Alexander Boes 1*†, Nadja Voepel 1, Veronique Beiss 1, Gueven Edgue 1,
Thomas Rademacher 1, Markus Sack 2, Stefan Schillberg 1, Andreas Reimann 1 and
Rainer Fischer 1, 2
1 Fraunhofer Institute for Molecular Biology and Applied Ecology IME, Aachen, Germany, 2 Institute for Molecular
Biotechnology, RWTH Aachen University, Aachen, Germany
Despite decades of intensive research efforts there is currently no vaccine that provides
sustained sterile immunity against malaria. In this context, a large number of targets
from the different stages of the Plasmodium falciparum life cycle have been evaluated as
vaccine candidates. None of these candidates has fulfilled expectations, and as long as
we lack a single target that induces strain-transcending protective immune responses,
combining key antigens from different life cycle stages seems to be the most promising
route toward the development of efficacious malaria vaccines. After the identification
of potential targets using approaches such as omics-based technology and reverse
immunology, the rapid expression, purification, and characterization of these proteins,
as well as the generation and analysis of fusion constructs combining different promising
antigens or antigen domains before committing to expensive and time consuming clinical
development, represents one of the bottlenecks in the vaccine development pipeline.
The production of recombinant proteins by transient gene expression in plants is a robust
and versatile alternative to cell-based microbial and eukaryotic production platforms. The
transfection of plant tissues and/or whole plants using Agrobacterium tumefaciens offers
a low technical entry barrier, low costs, and a high degree of flexibility embedded within
a rapid and scalable workflow. Recombinant proteins can easily be targeted to different
subcellular compartments according to their physicochemical requirements, including
post-translational modifications, to ensure optimal yields of high quality product, and
to support simple and economical downstream processing. Here, we demonstrate the
use of a plant transient expression platform based on transfection with A. tumefaciens
as essential component of a malaria vaccine development workflow involving screens
for expression, solubility, and stability using fluorescent fusion proteins. Our results have
been implemented for the evidence-based iterative design and expression of vaccine
candidates combining suitable P. falciparum antigen domains. The antigens were also
produced, purified, and characterized in further studies by taking advantage of the
scalability of this platform.
Keywords: expression screening, heat stability, multi domain-fusion antigens, Nicotiana benthamiana plants,
Plasmodium falciparum, red fluorescent protein
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INTRODUCTION
Even though the first malaria vaccine, GSK′s Plasmodium
falciparum circumsporozoite protein (CSP)-based Mosquirix
(RTS,S), (Wilby et al., 2012) is expected to enter the market
within the next 6–12 months, there is still an urgent demand
for a malaria vaccine that reliably delivers long lasting protection
against infection, clinical manifestation and transmission of the
disease. RTS′S (Chattopadhyay et al., 2003; Richards et al., 2013;
Penny et al., 2015; Reddy et al., 2015; RTS,S Clinical Trials
Partnership, 2015) presents pre-erythrocytic stage epitopes and
targets the parasite in an early phase of its life cycle within
the human host. However, Mosquirix does not induce complete
protection, and efficacy decreases rapidly over the first 24
months after immunization (RTS,S Clinical Trials Partnership
et al., 2012; Moorthy et al., 2013). Various strategies must be
considered to develop a better malaria vaccine, including the
optimization of immune responses and immune memory against
well-known and well-characterized targets like PfCSP, by testing
different presentation strategies (e.g., viral vectored vaccines,
virus-like particles), formulations (virsosomes), delivery, and
immunization schemes, as well as the identification of alternative
and/or additional antigens to target the blood and sexual stages
of the parasite life cycle to overcome allelic diversity and also to
prevent immune evasion.
Significant effort has been invested into the identification of
a large number of potential malaria vaccine candidate antigens,
domains, and epitopes, and several been taken through pre-
clinical and even clinical development, but none of the candidates
tested thus far provides long-lasting, strain-transcending sterile
immunity. The available data indicate that the development
of better malaria vaccines face two major challenges, i.e., the
induction of a strong and long-lasting (durable) response, and the
identification and combination of appropriate epitopes as targets
to induce a neutralizing response.
Natural acquired immunity (NAI) against malaria (Doolan
et al., 2009) is observed in individuals from holoendemic areas
and requires several years and many (50–70) infections to
develop. Its most important function seems to be the control
of blood-stage parasitemia by IgG directed against merozoite
surface proteins. NAI-mediated protection from episodes of
clinical malaria rapidly ceases following reduced or diminished
exposure to repeated infections. This highlights the importance
of both the induction of strong and durable IgG responses as well
as the identification of optimal target antigens.
The different stages of the parasite life cycle are characterized
by sets of specific surface proteins (Druilhe et al., 1984),
many of them involved in important functions such as host
cell attachment and host cell invasion (Malpede and Tolia,
2014). Another feature of P. falciparum that complicates the
development of sustainable protective immune responses is
its ability to switch between different pathways of erythrocyte
invasion, involving different sets of proteins from two invasion
ligand families, i.e., erythrocyte-binding antigens (EBA) and
reticulocyte-binding antigens (Rh) (Persson et al., 2008).
Many epidemiological studies involving donors from malaria
endemic areas associate protective immunity with antibody
responses against various, predominantly merozoite antigens
(Osier et al., 2008) including PfMSP1, PfAMA1, PfMSP4,
PfMSP8, PfEBA175, and PfRIPR. Many of these proteins elicit
in vitro parasite growth-inhibitory antibody responses after
animal immunization experiments (Sim et al., 2001; Stowers
et al., 2002; Moss et al., 2012), but despite substantial efforts
(Richards et al., 2013; Penny et al., 2015; Reddy et al., 2015; RTS,S
Clinical Trials Partnership, 2015) the roles of these proteins
in protective immunity remains poorly understood, making it
difficult to select rational targets for the design of an ultimate
malaria vaccine candidate.
We therefore believe that one promising direction in malaria
vaccine development is the generation and testing of single
or multi-stage-specific, multi-domain constructs that combine
promising antigens or antigen domains in the context of one
or several fusion proteins, which should induce more diverse
and ideally strain-transcendent immune responses against all
three stages of the P. falciparum life cycle, and thus achieve a
greater degree of protection than existing vaccine candidates.
The successful design of such completely artificial fusion proteins
that combine isolated protein domains will inevitably result in
a completely new context for these elements and may affect
both the expression level and stability. This is an unpredictable
challenge that must be addressed empirically through iterative
design cycles featuring cloning and expression experiments.
In addition to the classic molecular farming approaches
(Fischer et al., 1999; Daniell et al., 2001; Fischer and Schillberg,
2006) using stable transgenic plants, different transient plant
expression systems (Kapila et al., 1997; Gleba et al., 2005, 2007;
Starkevic et al., 2015) are gaining more and more attention
as platforms for the manufacture of pharmaceutical proteins
such as antibodies (Hull et al., 2005; Huang et al., 2010) and
enzymes for emergency use (Rosenberg et al., 2015) and as
conventional regular therapeutics (Aviezer et al., 2009). These
transient expression systems are robust and scalable, and have
been used for the inexpensive and the time and cost-efficient
generation and testing of expression constructs including for
many antibodies and vaccine antigens from different pathogens
including targeting Human immunodeficiency virus (Rosenberg
et al., 2013), Ebola virus (Huang et al., 2010), Influenza virus
(D’Aoust et al., 2010; Landry et al., 2010), Dengue virus (Kim
et al., 2015), Yersinia pestis (Santi et al., 2006), and P. falciparum
(Davoodi-Semiromi et al., 2010; Feller et al., 2012; Jones et al.,
2013; Boes et al., 2014, 2015; Voepel et al., 2014; Beiss et al., 2015).
Here, we demonstrate the application of the classicalNicotiana
benthamiana/A. tumefaciens transient expression system to
accelerate the development of malaria vaccine candidates, using
as case studies a pre-erythrocytic stage multi-domain candidate,
a dual-stage multi-domain candidate, and a multi-stage multi-
domain candidate.
MATERIALS AND METHODS
Ethics Statement
The animal experiments were approved by the Landesamt für
Natur, Umwelt und Verbraucherschutz Nordrhein-Westfalen
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(LANUV), reference number 8.87.−51.05.30.10.077. All animals
received humane care according to the requirements of the
German Tierschutzgesetz, §8 Abs. 1 and the Guide for the
Care and Use of Laboratory Animals published by the National
Institutes of Health.
Bacteria, Plant Characterization, and
Parasites
A. tumefaciens strain GV3101::pMP90RK [GmR, KmR, RifR]
(Koncz and Schell, 1986) and N. benthamiana plants were used
for transient expression by agroinfiltration. According to Bally
et al. N. benthamiana isolates vary in the RNA-dependent RNA
polymerase 1 gene (Rdr1) and a 72 bp insertion leading to a
truncated version of the enzyme has been reported. To verify
the genotype in respect to the Rdr1 locus, we used PCR, to
amplify the respective region from genomic DNA prepared
from N. benthamiana (Accession number: AY574374) and
Nicotiana tabacum L. Petit Havana cultivar SR1 (Accession
number: AJ011576, control). Primers (Rdr1 forward primer:
5′-GTTAACGTATCCAATCGGGTTCTGCG-3′ and Rdr1
reverse Primer: 5′-CTGATTTGCCGAAAATCACCCATCC-3′)
were designed to cover the region potentially containing the
72 bp insertion (found in the N. benthamiana isolates LAB,
16C and SA Bally et al., 2015) compatible to N. benthamiana
as well as N. tabacum which does not carry the Rdr1 72
bp insertion. Fragment size analysis (Presentation 1 in
Supplementary Material) revealed the insertion phenotype
for the N. benthamiana used in our study. P. falciparum strain
NF54 (MRA-1000, MR4, Manassas, USA) was used for the
parasite assays.
Construction of the Plant Expression
Vector
Synthetic genes or PCR products encoding selected antigens
and antigen domains were inserted into pTRAkc-ERH at the
NcoI/NotI sites. Subsequent stacking of additional domains was
achieved by inserting EagI/NotI fragments following plasmid
linearization with NotI. Red fluorescent protein (RFP) fusion
genes were inserted into a NotI-linearized plasmid carrying the
RFP cDNA using the same approach (Figure 1). Restriction
enzymes were used according to the manufacturers’ instructions.
The sequences of the P. falciparum antigens are summarized in
Table 1.
Transient Expression in N. benthamiana
The expression vectors were introduced separately into A.
tumefaciens and were used for the infiltration of N. benthamiana
plants as previously described by Feller et al. (2012).
Extraction of Total Soluble Protein from
Leaves and Heat Precipitation
For initial screening, two leaf discs (diameter 1 cm) were
punched from infiltrated leaves, weighed, and extracted in 3mL
phosphate buffered saline (PBS) per gram of leaf material using
an electropistil. Insolublematerial was removed by centrifugation
(16,000 g for 5min) and the supernatants were used directly
FIGURE 1 | Plant expression cassette. Schematic presentation of the
expression cassettes in the plant binary expression vector pTRAkc-ERH.
CaMV 35Spromoter and terminator: promoter with duplicated enhancer and
terminator of the Cauliflower mosaic virus (CaMV) 35S RNA gene; 5′
untranslated region: 5′-UTR of the chalcone synthase gene from Petroselinum
crispum; signal peptide sequence: transit peptide sequence of the murine
antibody heavy chain; RFP, red fluorescent protein from Discosoma spp.
(Bevis and Glick, 2002); GOI, Gene of interest. The restriction sites used to
insert the GOI into the plant expression vector are indicated; His6 tag:
sequence encoding the six histidine affinity purification tag; ER-retention
signal: sequence encoding the SEKDEL ER-retention signal.
for SDS-PAGE, western blot analysis, and the quantification of
RFP fluorescence. An aliquot of the supernatant was heated
(70◦C for 5min) and analyzed in the same manner. For
the purification of E5, total soluble protein was extracted
from 230 g of vacuum-infiltrated leaves in a Waring blender
using 3mL of extraction buffer (PBS containing 500mM
NaCl, pH 7.4) per gram of leaf material. The pH of the
crude extract was adjusted to pH 8.0 using NaOH and the
extract was heated to 65◦C. Insoluble material was removed
by a combination of centrifugation (14,000 g for 15min) and
filtration.
Protein Purification
The E5 recombinant protein was purified from heat-treated
extracts first by immobilized metal affinity chromatography
(IMAC) using chelating Sepharose (GE Healthcare) charged
with nickel (NiSO4, 200mM). Unbound proteins were washed
away with PBS and bound proteins were eluted in a two-step
gradient using PBS containing 10 and 250mM imidazole,
respectively. IMAC elution fractions containing the target
protein E5 were desalted against 20mM Tris (pH 7.5) and
E5 was further purified by ion exchange chromatography
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TABLE 1 | Overview of P. falciparum antigens and antigen domains.
Antigen Abbreviation PlasmoDB
ID
Amino acid Size
[kDa]
Size RFP-Fusion
[kDa]
RFP
fluorescence in
leaves
RFP
fluorescence in
extract
PfMsp1-19_EGF1 19_1 PF3D7_0930300 I1608-V1648 4.8 32.4 +++ M
PfMsp8_EGF1 8_1 PF3D7_0502400 N489-D533 5.2 32.8 +++ H
PfMsp8_EGF2 8_2 PF3D7_0502400 D534-S576 4.8 32.4 +++ M
PfMsp4_EGF 4 PF3D7_0207000 L201-L247 5.3 32.9 +++ H
PfMsp10_EGF1 10_1 PF3D7_0620400 V414-P458 5.4 33.0 +++ L
PfMsp10_EGF2 10_2 PF3D7_0620400 K460-K501 4.5 32.1 +++ M
PfRipr_EGF6 R6 PF3D7_0323400 K771-I814 5.3 32.9 ++ M
PfMTRAP_TSR MT PF3D7_1028700 T25-E98 8.6 36.2 ++ M
PfCelTOS Ce PF3D7_1216600 F25-D182 17.4 45.0 ++ M
PfCSP_TSR CT PF3D7_0304600 P311-S383 8.2 35.8 +++ M
PfTRAP_TSR TT PF3D7_1335900 E239-K289 5.8 33.4 +++ L
PfSPATR_TSR ST PF3D7_0212600 E168-C250 10.2 37.8 + L
Pfs25 25 PF3D7_1031000 V24-T193 18.6 46.2 ++ M
Pfs230_C0 C0 PF3D7_0209000 E443-N586 16.0 43.6 ++ H
For each antigen, the table provides the name, a short abbreviation, the plasma DB identifier, the amino acid sequence, the calculated single domain size, the calculated size of the
corresponding RFP-fusion protein as well as the categorized fluorescence observed in intact leaves (+++, high fluorescence in leaves; ++, moderate fluorescence in leaves; +, low
fluorescence in leaves) and categorized concentration (based on RFP fluorescence) in crude extracts (H, Accumulation > 150µg/g FLW; M, Accumulation between 25 and150µg/g
FLW, and L, < 25µg/g FLW).
(IEX) using a prepacked HiTrap Q FF column. The E5
protein was eluted using a three-step gradient (20mM Tris
pH 7.5 with 240, 500 and 1000mM NaCl, respectively).
The buffer was exchanged against PBS overnight at 4◦C
using a Spectra/Por membrane (MWCO 6000–8000 g/mol;
SpectrumLabs). The samples were then concentrated using
Vivaspin centrifugal concentrators (Sartorius-Stedim Biotech
GmbH) and passed through a 0.22-µm sterile filter. The
protein concentration was determined by UV spectroscopy
at 280 nm and the recombinant protein was stored at
4◦C.
SDS-Page and Western Blot Analysis
SDS-PAGE and western blot analysis were carried out as
previously described by Boes et al. (2011). The western blots
were probed with rabbit anti His6 (Jackson ImmunoResearch)
and alkaline phosphatase (AP)-conjugated goat anti-rabbit
serum (Jackson ImmunoResearch) were used for detection. The
monoclonal antibody (mAb) 5.2 (MRA-94, MR4, Manassas,
USA), which recognizes the first epithelial growth factor (EGF)-
like domain of PfMsp1-19, was used for dot-blot analysis and was
detected using AP-conjugated goat anti-mouse serum (Jackson
ImmunoResearch).
Quantification of RFP
The RFP concentration in tobacco supernatants was measured
as previously described by Buyel and Fischer (2012) with minor
modifications. The standard curve was generated with purified
RFP ranging from 0 to 100µg/mL and the concentration was
determined by linear regression analysis.
Binding of Soluble and Insoluble
RFP-Fusion Proteins to Ni-NTA Magnetic
Agarose Beads
To assess the solubility of RFP and selected RFP-fusion proteins,
Ni2+-NTA magnetic agarose beads (Qiagen) were used in
combination with fluorescence microscopy. Infiltrated leaves
were homogenized as described above and 400µL PBS and
50µL of Ni-NTA magnetic agarose beads were added directly to
the pulp. After incubation for 30min with continuous shaking,
the beads were collected with a magnet, washed intensively
with PBS and analyzed under a fluorescence microscope (Leica
DMI6000/AF6000).
Mouse Immunization and Titer
Determination
Three BALB/c mice 6–8 weeks of age (Taconic) were immunized
intraperitoneally with 50µg E5 emulsified in Gerbu MM
adjuvant (Gerbu Biotechnik GmbH) on days 1, 14, 28, and
42. On each day, 5-µL blood samples were collected from the
tail vein, diluted 1:10 in PBS and stored at –20◦C. Fourteen
days after the last immunization, the mice were narcotized, and
blood was collected by cardiocentesis. After 1 h incubation at
room temperature, the blood was centrifuged (200 g for 2min
at room temperature) and the serum was separated from the
blood cells and stored at –20◦C. The titers were determined in
relation to the respective pre-immune samples taken directly
before immunization, as previously described by Voepel et al.
(2014) using the full fusion antigen, as well as the single domain
RFP fusion proteins (100 ng/well), to coat microtiter plates for
analysis by direct ELISA.
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Immunofluorescence Assays
Indirect immunofluorescence assays with E5-specific immune
sera were carried out using the schizonts and macrogametes of
P. falciparum strain NF54 as previously described by Boes et al.
(2014), Voepel et al. (2014), Beiss et al. (2015).
RESULTS
Expression Screening of Single-Domain
RFP-Fusion Proteins
To select suitable antigens and/or antigen domains for a
multi-domain fusion vaccine from a panel of candidates, we
generated N-terminal RFP-fusion constructs to easily investigate
the accumulation, solubility, integrity, and heat stability of each
protein by transient expression in N. benthamiana.
The initial selection of antigens and antigen domains was
primarily based on the availability of epidemiological and/or
experimental data indicating the immunological relevance or
potential protective efficacy of the antigens or antigen domains.
The heat treatment of clarified or crude plant extracts is a valuable
tool to simplify the downstream purification of recombinant
protein from plant material because this step removes the
majority of host cell proteins (HCPs) including RuBisCo (Buyel
et al., 2014) but this approach is only suitable for recombinant
proteins that resist temperature-induced denaturation. In this
approach we wanted to avoid the heat sensitivity we observed in
previous experiments with larger, more complex, or unstructured
P. falciparum proteins (data not shown). Therefore, we focused
on compact and stable domains featuring many disulfide bridges,
including EGF-like (Beeby et al., 2005) and thrombospondin type
1 repeat (TSR)-domains that are present in many P. falciparum
surface proteins.
We duly selected 14 P. falciparum antigens or antigen
domains (Table 1) from different developmental stages of
the parasite (pre-erythrocytic stage PfCelTOS, PfCSP_TSR,
PfTRAP_TSR, and Pf SPATR; blood stage PfMsp1-19_EGF1,
PfMsp4_EGF, PfMsp8_EGF1, PfMsp8_EGF2, PfMsp10_EGF1,
PfMsp10_EGF2, PfMTRAP_TSR, and PfRipr_EGF6; and sexual
stage Pfs25 and Pfs230-C0). Synthetic genes encoding each
antigen were codon optimized for N. benthamiana, cloned
into the expression cassette of the vector pTRAkc-RFP-ERH
(Figure 1), introduced into A. tumefaciens which were then
used for transient expression in N. benthamiana by the syringe
infiltration of single leaves from intact plants. The vectors
pTRAkc-RFP-ERH and pTRA-RFP-ZenH, the latter encoding
a RFP fusion with the maize γ-zein domain that is targeted to
protein bodies (Hofbauer et al., 2014) were used as controls
for insoluble aggregates. After incubation for 4–5 days, the
leaves were harvested and RFP fluorescence was visualized
using a simple red filter with a cold light source and a green
excitation filter. As shown in Figures 2A,B, representative
leaves under normal and fluorescent light display different
degrees of RFP fluorescence for each of the constructs. A
strong signal was seen in the leaves infiltrated with the controls
ER-retarded RFP, and protein body targeted RFP (ZenH), as
well as RFP-PfMsp1-19_EGF1 (19_1), RFP-PfMsp8_EGF1
FIGURE 2 | Visualization of RFP accumulation in infiltrated N.
benthamiana leaves. Accumulation of RFP-antigen fusion proteins can be
visualized under green light using a red filter (Rademacher et al., 2008).
Non-infiltrated (wt) and infiltrated N. benthamiana leaves infiltrated with
different RFP-fusion constructs under white light (A) and under green light (B).
(8_1), RFP-PfMsp8_EGF2 (8_2), RFP-PfTRAP_TSR (TT),
RFP-PfCSP_TSR (CT), RFP-PfMsp10_EGF1 (10_1), RFP-
PfMsp10_EGF2 (10_2), and RFP-PfMsp4_EGF1 (4). Moderate
signals were observed for RFP-PfRipr_EGF6 (R6), RFP-
PfCelTOS (Ce), RFP-PfMTRAP_TSR (MT), RFP-Pf 230-C0
(C0), and RFP-Pfs25 (25). RFP-Pf SPATR_TSR (ST) exhibited
minimal RFP fluorescence (see also Table 1, column 7).
The soluble RFP fusion proteins were quantified by extracting
total soluble protein from leaf discs taken from infiltrated
leaves (three biological replicates) and taking spectroscopic
fluorescence measurements before and after heat treatment
(5min at 70◦C). The concentrations were determined relative to
the RFP calibration curve as summarized in Figure 3 and also
Table 1(column 8). These results indicated that all the RFP-fusion
proteins were heat stable because no significant reduction in the
fluorescence signal was observed after heat treatment (Figure 3,
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red columns). A strong difference between the visual appearance
(Figure 2B) and measured fluorescence values was observed for
RFP-PfMsp10_EGF1, RFP-PfMsp10_EGF2, RFP-PfTRAP_TSR,
and RFP-ZenH (Figure 3).
To investigate the possibility that insoluble aggregates may
form during expression we analyzed six representative samples
(non-infiltrated, RFP, RFP-ZenH, RFP-PfMsp1-19_EGF1, RFP-
PfMsp10_EGF1, and RFP-Pf SPATR_TSR) by microscopy after
capturing the recombinant protein and/or aggregates from the
crude extract on Ni-NTA magnetic agarose beads. The images
(Figure 4 left and right panel) clearly illustrate the differences
between predominantly soluble proteins like the ER-targeted
RFP and the RFP-PfMsp1-19_EGF1 fusion (even distribution
of fluorescence signal), and insoluble or aggregated proteins
(fluorescent berry-like structures) like the protein body targeted
RFP-ZenH and apparently the RFP-PfMsp10_EGF1 fusion. For
the low-yielding RFP-Pf SPATR_TSR protein we observed the
soluble phenotype without indication for insoluble aggregates.
Finally, the expression, solubility, integrity, and heat stability
of all RFP-fusion proteins was analyzed by reducing SDS-
PAGE and western blot (Figures 5A,B) using the supernatant of
heat-treated soluble extracts. Most of the recombinant proteins
migrated in the region corresponding to their expectedmolecular
weight (Table 1). Both methods also revealed the presence
of covalently linked dimers of the RFP-fusion proteins, an
observation we have made with almost all RFP-fusion proteins
we have generated and tested under comparable conditions.
In accordance with these observations, the RFP-Pf SPATR_TSR
fusion protein (Figures 5A,B, lane 14) and also the insoluble
RFP-PfMsp10_EGF1 fusion protein (Figures 5A,B, lane 7)
could not be detected. For the RFP-PfCelTOS fusion protein
(Figure 5B, lane 12) a western blot to detect the His6 tag revealed
the presence of small amounts of degradation products in the
regions around 40 kDa (D3, Figure 5B) and 18 kDa (D1, D2,
Figure 5B) potentially representing proteolytic cleavage. The
band intensities in Coomassie stained gels and on western
blots did not always correlate well (e.g., RFP-PfCSP_TSR,
Figure 5B, lane 12, and Pf 230-C0, Figure 5B, lane 16), possibly
indicating differences in the accessibility of the His6 tag for
the different P. falciparum proteins. The pronounced difference
between the in-gel and western blot signals representing Pf 230-
C0 (Figures 5A,B, lane 16) may reflect the proteolytic cleavage
of a C-terminal fragment comprising the His6 tag (visible at
>15 kDa on the western blot, D4, Figure 5B).
Construction of the Pre-erythrocytic
Vaccine Candidate P3
Based on the screening results for protein domains fused
to RFP, we selected PfCelTOS (Ce), PfCSP_TSR (CT), and
PfTRAP_TSR (TT) for the construction of a pre-erythocytic
vaccine candidate. The pre-erythrocytic antigen Pf SPATR_TSR
was rejected due to its poor expression as a RFP-fusion protein,
while the apparently poorly soluble PfTRAP_TSR (TT) was
included because of its clinical relevance and hoping for
improved solubility in the different context of a new fusion
protein.
To investigate the integrity, expression, and heat stability of
the domains subsequently combined in the context of a fusion
protein, we generated three expression constructs (P1, P2, and
P3, Figure 6A) and tested them by transient expression followed
by heat precipitation, SDS-PAGE and western blot. As shown
in Figure 6B, all three variants, including the artificial fusion
proteins P2 and P3, could be produced at satisfactory levels
(>100µg/g fresh leaf weight (FLW) based on our judgment of
in-gel band intensities after Coomassie staining, according to
our previous experiences) and remained in the soluble fraction
FIGURE 3 | Quantification of RFP-fusion proteins in plant extracts before and after heat treatment by fluorescence detection. The accumulation of
RFP-fusion proteins was determined by fluorescence quantification compared to affinity-purified RFP-derived calibration curve. Values are expressed as mean of three
biological replicates including standard deviations. Gray columns, crude extract; red columns, extract after heat treatment; lanes 3–16 contain the samples identified
in Table 1. FLW, fresh leaf weight.
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FIGURE 4 | Visualization of insoluble aggregate formation. Analysis
of selected RFP-fusion proteins after purification from plant crude extracts using
(Continued)
FIGURE 4 | Continued
Ni-NTA magnetic agarose beads, showing the difference between soluble and
insoluble proteins. Wt, non-infiltrated leaf extract; RFP, RFP construct;
19_1,RFP-PfMsp1-19_EGF1 construct; ST, RFP-PfSPATR_TSR; RFP-ZenH;
10_1, RFP-PfMsp10_EGF1. Left panel, Transmission image; right panel,
fluorescence image.
after heat treatment. Bands corresponding to P1 (calculated
size 19.3 kDa, observed size 19–20 kDa), P2 (calculated size
27.7 kDa, observed size: 32–34 kDa), and P3 (calculated size
33.9 kDa, observed size 38–40 kDa) were clearly represented on
the stained gel and corresponding His6 tag-specific western blot
representing extracts after heat treatment, indicating that the
combination of PfCelTOS with the TSR domains of PfCSP-TSR
and PfTRAP_TSR within a fusion construct yields an intact and
heat-stable protein that combines important complementary P.
falciparum pre-erythrocytic antigens. For the fusion proteins P2
and P3, the western blot revealed the formation of reduction-
insensitive higher-molecular-weight aggregates with an apparent
molecular weight of the corresponding dimers (64–68 kDa for the
P2 dimer and 76–80 kDa for the P3 dimer), whereas only a small
amount of the C-terminal (His6-tagged) degradation product
was observed at 11 kDa, suggesting that the partial proteolytic
degradation of PfCelTOS as observed in the expression screening
of single domain RFP-fusion proteins (Figure 5) does not occur
to the same extent in the context of the P3 fusion protein.
Construction, Expression, Purification, and
Characterization of the Multi-EGF
Dual-Stage Vaccine Candidate E5
EGF-like domains are present in several P. falciparum surface
proteins, predominantly on the merozoites and schizonts
(blood stage) but also on the zygotes, macrogametes, and
ookinetes (sexual stage). Whereas GPI-anchored merozoite
surface proteins such as PfMsp4 and PfMsp5 feature single
EGF-like domains, PfMsp1, PfMsp8, and PfMsp10 feature a
tandem array of two EGF-like domains, and the sexual stage
antigen Pfs25 is composed of four EGF-like domains. The
merozoite surface antigen PfRipr contains a total of 10 EGF-
like domains arranged in a tandem followed by a separate
cluster of eight EGF-like domains. It has been shown that
EGF-like domains are the target of parasite growth inhibitory
antibodies in humans (Egan et al., 1999; O’Donnell et al., 2001;
Maskus et al., 2015) and/or immunized animals (Chappel and
Holder, 1993; Chen et al., 2011) and improve the antigenicity
of the antigens (Wang et al., 1999). The high expression
levels and thermal stability of most of the EGF-like domain
constructs in our panel prompted us to combine a number of
such domains from P. falciparum merozoites with the sexual
stage antigen Pfs25 in the context of a multi-EGF dual-stage
vaccine candidate antigen. Taking into account the expression
levels and solubility data obtained in the RFP-fusion expression
screening experiments, we omitted PfMsp10_EGF1/2. Using a
domain stacking approach, a series of five sequentially elongated
constructs (E1–E5) was generated, the largest of which was E5
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FIGURE 5 | SDS-PAGE and western blot analysis of RFP-fusion proteins. SDS-PAGE (A) and western blot analysis (B) of heat-treated plant extracts obtained
from infiltrated N. benthamiana leaves under reducing conditions. Proteins were detected using rabbit anti-His6 and alkaline phosphatase-labeled goat anti-rabbit
antiserum. M, PageRulerTM pre-stained protein ladder (Fermentas); wt, non-infiltrated leaf extract; lane 1, RFP; lane 2, RFP-ZenH, lanes 3–16 contain the samples
identified in Table 1. *Putative monomeric RFP/RFP-fusions; **putative cross-linked dimeric forms of RFP-fusions. D1-4, putative degradation products.
comprising PfMsp1-19_EGF1, PfMsp8_EGF1/2, PfMsp4_EGF,
and Pfs25 (Figure 7A). Heat-treated extracts from syringe-
infiltrated leaf material at 5 dpi were analyzed by SDS-PAGE
and western blot. As shown in Figure 7B, the smallest expression
construct (construct E1, featuring PfMsp1-19_EGF1 alone) was
not detected in the heat-treated extract by a His6 tag-specific
western blot, but the presence of the protein was confirmed,
alone and in the context of the different successor fusion
proteins, using a conformational, reduction-sensitive PfMsp1-
19_EGF1-specific monoclonal antibody in a dot-blot under
native conditions (Figure 7C). Although construct E2 combining
PfMsp1-19_EGF1 and PfMsp4_EGF showed weak expression,
the larger variants E3, E4, and E5 accumulated to satisfactory
levels that were easily detected by Coomassie staining. A
15 kDa C-terminal degradation fragment comprising the His6 tag
observed in the case of construct E3 and a weaker 25 kDa His6-
taged degradation fragment observed for construct E5, indicate
that the fusion proteins are not completely resistant to proteolytic
cleavage.
To provide material for immunization studies, E5 was
produced and purified from 200 g of vacuum infiltrated N.
benthamiana leaves. Purification by IMAC and IEX yielded a final
4mg preparation of highly pure (>90%) protein (Figure 8A)
corresponding to 15µg of purified E5 per gram of fresh leaf
material.
The purified E5 fusion antigen was used to immunize mice
and the resulting immune sera were analyzed for E5 titers as well
as single domain-specific titers by ELISA. As shown in Figure 8B,
the immune response was directed against all domains and the
average titer against the single domains ranged from around
70,000 for PfMsp1-19_EGF1 to around 450,000 for Pfs25. The
titer measured against the full fusion antigen was >500,000. For
crude ELISA data refer to data sheet 1. Additionally, the ability
of the E5 fusion antigen to induce antibodies that recognize
P. falciparum antigens in their native context was determined
by immunofluorescence analysis involving different parasite
preparations from the blood and sexual stages. Figures 8C,D
show that the E5-specific mouse immune sera bind to parasite
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FIGURE 6 | Construction and expression of the pre-erythrocytic stage
candidate (variants P1–P3). (A) Construct architecture. For antigen
abbreviations refer to Table 1. (B) SDS-PAGE and western blot analysis of
pre-erythrocytic stage candidate variants. Heat-treated crude extracts were
separated under reducing conditions and analyzed by staining with
Coomassie (left panel) or by western blot using rabbit anti-His6 and alkaline
phosphatase-labeled goat anti-rabbit antiserum. M, PageRulerTM pre-stained
protein ladder (Fermentas); wt, non-infiltrated leaf extract.
surface proteins in their native context (schizonts, blood stage
parasites, Figure 8C, and macrogametes, sexual stage parasites,
Figure 8D) and provide an indication that PfEGFs are correctly
folded when combined within the E5 fusion protein.
Construction and Expression of the
Multi-Domain, Multi-Stage Vaccine
Candidate M8
After gaining promising results with the P3 and E5 fusion
proteins, we next used the transient expression platform for the
stepwise generation of the multi-domain, multi-stage vaccine
candidate fusion protein M8. Starting from a four EGF-
domain variant featuring PfMsp1-19_EGF1, PfMsp8_EGF1/2,
and PfMsp4_EGF, we subsequently added seven additional
previously screened domains (Figure 9A) representing all three
main parasite stages, and analyzed the accumulation and heat
stability of the fusion proteins by SDS-PAGE and western blot.
Figure 9B shows that all eight multi-domain fusion proteins
were detected in heat-treated crude extracts when the proteins
FIGURE 7 | Construction and expression of the multi-EGF dual-stage
vaccine candidate (variants E1–E5). (A) Construct architecture. For antigen
abbreviations refer to Table 1. (B) SDS-PAGE and western blot analysis of
dual-stage candidate variants. Heat-treated crude extracts were separated
under reducing conditions and analyzed by staining with Coomassie (left
panel) or by western blot using rabbit anti-His6 and alkaline
phosphatase-labeled goat anti-rabbit antiserum. M, PageRulerTM pre-stained
protein ladder (Fermentas); wt, non-infiltrated leaf extract. (C) Dot-blot analysis
of heat-treated crude extracts detected under non-reducing conditions using a
PfMsp1-19_EGF1-specific monoclonal antibody to confirm minimal
expression of the single EGF1 domain of PfMsp1-19 and the proper folding of
this domain. Binding was detected using goat anti-mouse alkaline
phosphatase-labeled antiserum.
were separated by SDS-PAGE under reducing conditions and
stained with Coomassie (Figure 9B, left side). The proteins
were also detected by His6 tag-specific western blot (Figure 9B,
right side). In both cases, the proteins migrated as expected
for their molecular weights. The western blot revealed a
number of higher-molecular-weight aggregates especially for
the larger fusion proteins (Figure 9B, right side, lanes 3–
8) as well as small amounts of (His6-tagged) degradation
products. Two of the degradation products previously observed
for RFP-PfCelTOS (D1, D2, Figure 5B) were also observed
for the PfCelTOS-containing fusion proteins (Figure 9B, right
side, lanes 3, 7, and 8) with increasing size correlating
with the size of the fusion partners distal to the PfCelTOS
component.
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FIGURE 8 | Initial characterization of E5-specific immune responses. (A) SDS-PAGE analysis of purified E5. M, PageRulerTM pre-stained protein ladder
(Fermentas); E5, 15µg of purified E5 under reducing conditions. (B) Domain-specific titer analysis of E5-specific murine immune sera. Titers were derived by
direct-coating ELISA against purified single-domain RFP-fusions (data not shown) and are defined as the dilution that gives more than twice the value of pre-immune
serum. Titers for the individual animals are given (M1–M3) as well as the geometric mean (horizontal solid black line). For domain identification refer to Table 1. (C,D)
Immunofluorescence assay of P. falciparum NF54 parasites at two different stages. (C) Schizonts (blood stage) and (D) macrogametes (sexual stage) were fixed with
methanol on the surface of a slide. Detection with IgGs from mice immunized with E5 is shown as a representative example. Rabbit antisera, PfMsp1-19 (schizonts)
and Pfs25 (magrogametes) were used as positive controls. Rabbit controls were visualized with an anti-rabbit secondary antibody labeled with Alexa Fluor 594 (red)
whereas murine immune IgG was visualized with a secondary Alexa Fluor 488 labeled anti-murine antibody (green). (I) murine immune IgG; (II) counterstaining with
stage-specific rabbit antiserum; (III) neutral mouse serum; (IV) counterstaining with stage-specific rabbit antiserum.
DISCUSSION
RFP-Fusion Protein Based Expression
Screening as Vaccine Development Tool
Over the last few decades, a large number of P. falciparum
antigens from different lifecycle stages have been proposed
as potential malaria vaccine candidates (Moorthy and Hill,
2001; Todryk and Hill, 2007). Many of them have been
tested in preclinical animal studies, some yielding promising
results, others yielding ambiguous, or negative outcomes. Taken
together, the available data suggest that one route toward a
more efficacious malaria vaccine could be the combination
of different antigens or antigen domains to broaden the
immune response against multiple targets, even targets from
different stages to achieve multi-stage protective efficacy (Hill,
2011).
Based on these considerations, we implemented a malaria
vaccine development program using our well-established plant
transient expression platform based on A. tumefaciens. The
screening of RFP-fusion protein expression provided an efficient
tool to rapidly assess the expression and solubility of large
numbers of vaccine antigens. RFP supports both N-terminal
and C-terminal fusions, accumulates to high levels in different
subcellular compartments and has been used to analyze protein
targeting and/or localization (Pasare et al., 2013), as a visual
marker for transgene expression (Rademacher et al., 2008;
Sack et al., 2015), to address and compare the efficiency of
transfection methodologies (Leuzinger et al., 2013), and to
develop predictive models for transient gene expression in
tobacco (Buyel and Fischer, 2012). The strong fluorescence of
the mature homotetrameric structure is simple to detect and
quantify, making it an ideal reporter for expression screening.
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FIGURE 9 | Construction and expression of the multi-domain, multi-stage vaccine candidate (variants M1–M8). (A) Construct architecture. For antigen
abbreviations refer to Table 1. (B) SDS-PAGE and western blot analysis of multi-domain, multi-stage candidate variants. Heat-treated crude extracts were separated
under reducing conditions and analyzed by staining with Coomassie (left panel) or by western blot using rabbit anti-His6 and alkaline phosphatase-labeled goat
anti-rabbit antiserum. M, PageRulerTM pre-stained protein ladder (Fermentas); wt, non-infiltrated leaf extract.
The syringe infiltration of single leaves allows the
straightforward comparative testing of up to six constructs in a
single plant, using an A. tumefaciens suspension prepared from a
5-mL culture grown in standard test tubes. Visual inspection of
RFP fluorescence in planta provides the first readout of construct
functionality, whereas solubility and heat stability can be assessed
visually at the macroscopic or microscopic levels in planta, and
after extract preparation, processing, and centrifugation. Heat
stability is favorable because it facilitates the removal of HCPs
during downstream processing (Buyel et al., 2014; Voepel et al.,
2014; Beiss et al., 2015) and potentially translates into favorable
storage and shelf-life properties. In the context of our panel of
14 candidates, this screen quickly identified poorly expressed
proteins such as Pf SPATR_TSR and PfMsp10_EGF2, as well as
insoluble proteins such as PfMsp10_EGF1 and PfTRAP_TSR.
In addition to immunological and clinical considerations,
information about domain folding and the number of disulfide
bridges was an important criterion during the selection of our
panel of P. falciparum antigens. In contrast to the large, often
redundant and unstructured characteristics of P. falciparum
surface antigens (Feng et al., 2006), both EGF-like and TSR
domains are highly structured and rich in disulfide bridges.
This pre-selection process explains why we did not find any
heat-sensitive proteins during the screen. The use of RFP as
a fusion partner provided an additional advantage because it
enabled the analysis of small proteins (like single EGF-like
domains) which sometimes do not accumulate to detectable
levels when expressed alone. One example is PfMsp1-19_EGF1,
which was subsequently introduced successfully into multi-
domain fusion proteins (Boes et al., 2015). Furthermore, RFP-
domain fusion proteins are also needed for the deconvolution
of antibody responses against vaccine candidates comprising
multiple domains and components.
Assembly of the Pre-erythrocytic Stage
Candidate P3
After selecting soluble and heat stable pre-erythrocytic stage
antigens using the transient expression platform to screen RFP-
fusion proteins, we generated sequentially elongated fusion
protein variants and developed the novel pre-erythrocytic multi-
domain vaccine candidate P3. We confirmed that P3, the
largest variant composed of three different antigens or antigen
domains, was expressed as an intact fusion protein at satisfactory
levels and remained soluble after heat treatment to remove
HCPs.
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P3 was thus regarded as a promising pre-erythrocytic
vaccine candidate and was selected for further investigations.
The production, purification, and characterization of P3
(renamed CCT in later studies) has been described in
detail elsewhere, including results confirming the in vitro
inhibition of pre-erythrocytic parasite stages by P3-specific
mouse immune sera (Voepel et al., 2014). P3 was also
selected as part of a plant-derived multi-stage vaccine
cocktail that underwent detailed characterization in rabbit
immunization studies and in vitro parasite inhibition assays
at different life cycle stages (Boes et al., 2015). These studies
confirmed its pre-erythrocytic stage efficacy (up to 80%
inhibition of pre-erythrocytic parasites in vitro) following
the immunization of rabbits. Upstream production, and
downstream process development for the large-scale transient
expression of P3 in N. benthamiana is presented in a separate
publication in this issue, including the optimization of buffer
conditions and the heat treatment process (Menzel et al., in
preparation).
Construction, Expression Purification, and
Characterization of the Multi-EGF
Dual-Stage Vaccine Candidate E5
By analogy to the construction of the single stage (pre-
erythrocytic stage) multi-domain vaccine candidate P3 we
performed the generation of the dual-stage (blood stage and
sexual stage) multi-domain vaccine candidate E5 as an assembly
of EGF-like domains from three different blood stage antigens
and one sexual stage antigen. The EGF-like domain is a small
(30–40 amino acids) and well-conserved fold found in many
proteins from diverse species and typically features three intra-
domain disulfide bounds (Wouters et al., 2005). Even though
the EGF-like domain is stable, our initial experiments with
the EGF-like domains from different P. falciparum antigens
revealed large differences in expression and accumulation (data
not shown). The RFP-fusion expression screening approach
made it possible to reject problematic EGF-like domains
such as PfMsp10_EGF1 and 2 and only combine strongly-
expressed soluble domains to construct the E5 vaccine candidate
antigen.
The purified protein was used in an initial mouse
immunization study to determine the titers against the full-
size fusion protein and its individual domains. The overall titers
of >500,000 indicated robust immunogenicity, and although
the small number (three) of animals used in this immunization
study prevented thorough statistical evaluation, the strong
immune response against the largest component (Pfs25,
four EGF-like domains) compared to the other components
(PfMsp1-19_EGF1, PfMsp8-_EGF1, PfMsp8_EGF2, and
PfMsp4_EGF, each featuring one EGF-like domain) matches
our observations concerning multi-domain, multi component
vaccines in previous studies (Boes et al., 2015; Spiegel et al., 2015)
confirming the positive correlation between component size and
immune response and thereby provides useful guidelines for the
development of a multi-domain, multi-stage, multi-allele vaccine
cocktail.
Construction and Expression of the
Multi-Domain, Multi-Stage Vaccine
Candidate M8
We also used the workflow described above for the stepwise
construction and expression of a large multi-domain, multi-
stage vaccine candidate named M8. Based on the selection
of P. falciparum antigen domains with confirmed strong
expression, integrity, heat stability, and suitability as components
of fusion antigens, we were able to produce a complex
fusion protein consisting of 11 different promising vaccine
candidate antigens and antigen domains in the context of a
heat stable, moderately expressed, and proteolytically stable
protein. Following the optimization of downstream processing,
the M8 vaccine candidate will be produced, purified, and
tested in animal immunization studies and parasite growth
inhibition assays using the three main stages of the P.
falciparum life cycle. These results will be particularly interesting
with respect to conclusions that have been drawn in the
context of results the authors have generated by immunization
experiments with the pre-erythrocytic vaccine candidate P3
(Voepel et al., 2014), a sexual stage vaccine candidate (F0)
containing Pfs25 and Pfs230_Co (Beiss et al., 2015) as well
as with a malaria multi-component vaccine cocktail (amomg
others including P3 and F0; Boes et al., 2015) and multi-
stage fusion proteins (Spiegel et al., 2015). In these studies
it could be shown that the combination of candidates that
provide good in vitro efficacy may lead to unwanted reduction
of titers against single components by antigenic competition.
On the other hand low immunogenic components like PfMsp1-
19 seem to profit from presentation in the context of fusion
proteins that provide additional t-cell epitopes. Taking the
available data together it becomes clear that these effects are
poorly predictable. The authors observed an unproportionally
high immune response against PfCSP_TSR in the context of
P3, while in the studies working with larger fusion proteins
and cocktails the distribution of component-specific titers did
roughly correlate with the molar quantity of the component
within the mixture and/or fusion. It will be interesting to see
what advantages and disadvantages can be observed in the
case of M8 that combines interesting pre-erythrocytic, sexual,
and blood stage antigens in the context of a large fusion
protein.
CONCLUSIONS AND FUTURE
PERSPECTIVES
In this study we have demonstrated the successful application
of a plant-based transient expression platform as an essential
tool for the development of multi-domain, multi-stage malaria
vaccine candidates. The simple and robust workflow based on
syringe infiltration requires only a small number of plants and
small culture volumes. This allows the convenient analysis several
samples in parallel in a time frame from gene to protein of <10
days. The method can easily be scaled up from 100µg scale
(leaf discs) realized by syringe infiltration of leaves up to 100
g (whole leaves) scale realized by vacuum infiltration of whole
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plants, enabling the convenient generation of mg-amounts of
target protein for advanced analytics or animal immunization
studies. Providing a generic toolbox, the established workflow
and methodologies can be easily translated to successfully
address any vaccine candidate identification and development
task.
AUTHOR CONTRIBUTIONS
HS participated in the design of the experiments, performed
the experiments, performed data interpretation, and drafted the
manuscript. AB participated in the design of the experiments,
performed the experiments, performed data interpretation, and
drafted the manuscript. NV participated in the work related to
the pre-erythrocytic stage vaccine candidate P3 and helped in
drafting the manuscript. VB was involved in antigen selection
and performed the cloning of sexual stage antigen constructs
and helped in drafting the manuscript. GE was involved in
antigen selection and performed the cloning of TSR-domain
fusion constructs and helped in drafting the manuscript. TR
participated in the design of the experiments and performed the
cloning and testing of RFP-control constructs. MS participated
in the study design and the data interpretation and revised the
manuscript. SS participated in study design and coordination,
and helped to draft the manuscript. AR participated in the study
design and the data interpretation, and revised the manuscript.
RF conceived of the study, participated in its design and revised
the manuscript.
FUNDING
This work was funded by the Fraunhofer-Zukunftsstiftung
(Fraunhofer Future Foundation).
ACKNOWLEDGMENTS
MRA-94 (mAb 5.2) deposited by David C. Kaslow was obtained
through theMR4 as part of the BEI Resources Repository, NIAID,
NIH. The authors are grateful to Ibrahim Al Amedi (RWTH
Aachen University, Germany) for cultivating the tobacco plants
used in this study. We thank Matthias Scheuermayer (University
of Wuerzburg) for performing the immunofluorescence assays
and Thomas Schmelter (Fraunhofer IME, Aachen, Germany)
for assistance with image acquisition. We also thank Leonie
Fritsch for assistance with the Agilent 2100 Bioanalyzer and Julia
Zischewski for providing genomic DNA. We thank Alessandro
Vitale (Institute of Agricultural Biology and Biotechnology,
Milano) for providing a plasmid featuring the protein body
targeting sequence. We also thank Dr. RichardM Twyman
(Twyman Research Management Ltd., York, UK) for manuscript
editing.
SUPPLEMENTARY MATERIAL
The Supplementary Material for this article can be found
online at: http://journal.frontiersin.org/article/10.3389/fpls.2015.
01169
REFERENCES
Aviezer, D., Brill-Almon, E., Shaaltiel, Y., Hashmueli, S., Bartfeld, D., Mizrachi,
S., et al. (2009). A plant-derived recombinant human glucocerebrosidase
enzyme—a preclinical and phase I investigation. PLoS ONE 4:e4792. doi:
10.1371/journal.pone.0004792
Bally, J., Nakasugi, K., Jia, F., Jung, H., Ho, S. Y. W., Wong, M., et al. (2015). The
Extremophile Nicotiana benthamiana has traded viral defence for early vigour.
Nat. Plants 1:15165. doi: 10.1038/nplants.2015.165
Beeby, M., O’Connor, B. O., Ryttersgaard, C., and Boutz, D. R. (2005). The
genomics of disulfide bonding and protein stabilization in thermophiles. PLoS
Biol. 3:e309. doi: 10.1371/journal.pbio.0030309
Beiss, V., Spiegel, H., Boes, A., Kapelski, S., Scheuermayer, M., Edgue, G., et al.
(2015). Heat-precipitation allows the efficient purification of a functional
plant-derived malaria transmission-blocking vaccine candidate fusion protein.
Biotechnol. Bioeng. 112, 1297–1305. doi: 10.1002/bit.25548
Bevis, B. J., and Glick, B. S. (2002). Rapidly maturing variants of the Discosoma
red fluorescent protein (DsRed). Nat. Biotechnol. 20, 83–87. doi: 10.1038/
nbt0102-83
Boes, A. A., Spiegel, H. H., Delbrück, H. H., Fischer, R. R., Schillberg, S. S.,
and Sack, M. M. (2011). Affinity purification of a framework 1 engineered
mouse/human chimeric IgA2 antibody from tobacco. Biotechnol. Bioeng. 108,
2804–2814. doi: 10.1002/bit.23262
Boes, A., Spiegel, H., Edgue, G., Kapelski, S., Scheuermayer, M., Fendel,
R., et al. (2014). Detailed functional characterization of glycosylated and
nonglycosylated variants of malaria vaccine candidate PfAMA1 produced in
Nicotiana benthamiana and analysis of growth inhibitory responses in rabbits.
Plant Biotechnol. J. 13, 222–234. doi: 10.1111/pbi.12255
Boes, A., Spiegel, H., Voepel, N., Edgue, G., Beiss, V., Kapelski, S., et al.
(2015). Analysis of a multi-component multi-stage malaria vaccine
candidate-tackling the cocktail challenge. PLoS ONE 10:e0131456. doi:
10.1371/journal.pone.0131456
Buyel, J. F., and Fischer, R. (2012). Predictive models for transient protein
expression in tobacco (Nicotiana tabacum L.) can optimize process time,
yield, and downstream costs. Biotechnol. Bioeng. 109, 2575–2588. doi:
10.1002/bit.24523
Buyel, J. F., Gruchow, H. M., Boes, A., and Fischer, R. (2014). Rational design of a
host cell protein heat precipitation step simplifies the subsequent purification
of recombinant proteins from tobacco. Biochem. Eng. 88, 162–170. doi:
10.1016/j.bej.2014.04.015
Chappel, J. A., and Holder, A. A. (1993). Monoclonal antibodies that inhibit
Plasmodium falciparum invasion in vitro recognise the first growth factor-like
domain of merozoite surface protein-1. Mol. Biochem. Parasitol. 60, 303–311.
doi: 10.1016/0166-6851(93)90141-J
Chattopadhyay, R., Rathore, D., Fujioka, H., Kumar, S., de la Vega, P.,
Haynes, D., et al. (2003). PfSPATR, a Plasmodium falciparum protein
containing an altered thrombospondin type I repeat domain is expressed
at several stages of the parasite life cycle and is the target of inhibitory
antibodies. J. Biol. Chem. 278, 25977–25981. doi: 10.1074/jbc.M3008
65200
Chen, L., Lopaticki, S., Riglar, D. T., Dekiwadia, C., Uboldi, A. D., Tham, W.-H.,
et al. (2011). An EGF-like protein forms a complex with PfRh5 and Is required
for invasion of human erythrocytes by Plasmodium falciparum. PLoS Pathog.
7:e1002199. doi: 10.1371/journal.ppat.1002199
D’Aoust, M.-A., Couture, M. M. J., Charland, N., Trépanier, S., Landry, N., Ors,
F., et al. (2010). The production of hemagglutinin-based virus-like particles
in plants: a rapid, efficient and safe response to pandemic influenza. Plant
Biotechnol. J. 8, 607–619. doi: 10.1111/j.1467-7652.2009.00496.x
Daniell, H. H., Streatfield, S. J. S., and Wycoff, K. K. (2001). Medical
molecular farming: production of antibodies, biopharmaceuticals and edible
Frontiers in Plant Science | www.frontiersin.org 13 December 2015 | Volume 6 | Article 1169
Spiegel et al. Transient Plant Expression-Based Vaccine Development
vaccines in plants. Trends Plant Sci. 6, 219–226. doi: 10.1016/S1360-1385(01)0
1922-7
Davoodi-Semiromi, A., Schreiber, M., Nalapalli, S., Verma, D., Singh, N. D., Banks,
R. K., et al. (2010). Chloroplast-derived vaccine antigens confer dual immunity
against cholera and malaria by oral or injectable delivery. Plant Biotechnol. J. 8,
223–242. doi: 10.1111/j.1467-7652.2009.00479.x
Doolan, D. L., Dobaño, C., and Baird, J. K. (2009). Acquired immunity to malaria.
Clin. Microbiol. Rev. 22, 13–36. doi: 10.1128/CMR.00025-08
Druilhe, P., Puebla, R. M., Miltgen, F., Perrin, L., and Gentilini, M. (1984). Species-
and stage-specific antigens in exoerythrocytic stages of Plasmodium falciparum.
Am. J. Trop. Med. Hyg. 33, 336–341.
Egan, A. F., Burghaus, P., Druilhe, P., Holder, A. A., and Riley, E. M.
(1999). Human antibodies to the 19kDa C-terminal fragment of Plasmodium
falciparummerozoite surface protein 1 inhibit parasite growth in vitro. Parasite
Immunol. 21, 133–139. doi: 10.1046/j.1365-3024.1999.00209.x
Feller, T., Thom, P., Koch, N., Spiegel, H., Addai-Mensah, O., Fischer, R., et al.
(2012). Plant-based production of recombinant Plasmodium surface protein
pf38 and evaluation of its potential as a vaccine candidate. PLoS ONE 8:e79920.
doi: 10.1371/journal.pone.0079920
Feng, Z.-P., Zhang, X., Han, P., Arora, N., Anders, R. F., and Norton, R. S. (2006).
Abundance of intrinsically unstructured proteins in P. falciparum and other
apicomplexan parasite proteomes. Mol. Biochem. Parasitol. 150, 256–267. doi:
10.1016/j.molbiopara.2006.08.011
Fischer, R., and Schillberg, S. (2006).Molecular Farming. Hoboken, NJ: JohnWiley
& Sons.
Fischer, R., Vaquero-Martin, C., Sack, M., Drossard, J., Emans, N., and
Commandeur, U. (1999). Towards molecular farming in the future: transient
protein expression in plants. Biotechnol. Appl. Biochem. 30(Pt 2), 113–116.
Gleba, Y., Klimyuk, V., and Marillonnet, S. (2007). Viral vectors for the
expression of proteins in plants. Curr. Opin. Biotechnol. 18, 134–141. doi:
10.1016/j.copbio.2007.03.002
Gleba, Y., Klimyuk, V., andMarillonnet, S. S. (2005).Magnifection–a new platform
for expressing recombinant vaccines in plants. Vaccine 23, 2042–2048. doi:
10.1016/j.vaccine.2005.01.006
Hill, A. V. S. (2011). Vaccines against malaria. Philos. Trans. R. Soc. Lond. B Biol.
Sci. 366, 2806–2814. doi: 10.1098/rstb.2011.0091
Hofbauer, A., Peters, J., Arcalis, E., Rademacher, T., Lampel, J., Eudes, F., et al.
(2014). The induction of recombinant protein bodies in different subcellular
compartments reveals a cryptic plastid-targeting signal in the 27-kDa γ-Zein
Sequence. Front. Bioeng. Biotechnol. 2:67. doi: 10.3389/fbioe.2014.00067
Huang, Z., Phoolcharoen, W., Lai, H., Piensook, K., Cardineau, G., Zeitlin, L.,
et al. (2010). High-level rapid production of full-size monoclonal antibodies in
plants by a single-vector DNA replicon system. Biotechnol. Bioeng. 106, 9–17.
doi: 10.1002/bit.22652
Hull, A. K., Criscuolo, C. J., Mett, V., Groen, H., Steeman, W., Westra,
H., et al. (2005). Human-derived, plant-produced monoclonal
antibody for the treatment of anthrax. Vaccine 23, 2082–2086. doi:
10.1016/j.vaccine.2005.01.013
Jones, R. M., Chichester, J. A., Mett, V., Jaje, J., Tottey, S., Manceva,
S., et al. (2013). A plant-produced Pfs25VLP malaria vaccine candidate
induces persistent transmission blocking antibodies against Plasmodium
falciparum in immunizedmice. PLoS ONE 8:e79538. doi: 10.1371/journal.pone.
0079538
Kapila, J., De Rycke, R., Van Montagu, M., and Angenon, G. (1997). An
agrobacterium-mediated transient gene expression system for intact leaves.
Plant Sci. 122, 101–108. doi: 10.1016/S0168-9452(96)04541-4
Kim, M.-Y., Reljic, R., Kilbourne, J., Ceballos-Olvera, I., Yang, M.-S., Reyes-del
Valle, J., et al. (2015). Novel vaccination approach for dengue infection based
on recombinant immune complex universal platform. Vaccine 33, 1830–1838.
doi: 10.1016/j.vaccine.2015.02.036
Koncz, C., and Schell, J. (1986). The promoter of TL-DNA gene 5 controls
the tissue-specific expression of chimaeric genes carried by a novel type
of Agrobacterium binary vector. Mol. Gen. Genet. MGG 204, 383–396. doi:
10.1007/bf00331014
Landry, N., Ward, B. J., Trépanier, S., Montomoli, E., Dargis, M., Lapini, G.,
et al. (2010). Preclinical and clinical development of plant-made virus-like
particle vaccine against avian H5N1 influenza. PLoS ONE 5:e15559. doi:
10.1371/journal.pone.0015559
Leuzinger, K., Dent, M., Hurtado, J., Stahnke, J., Lai, H., Zhou, X., et al.
(2013). Efficient agroinfiltration of plants for high-level transient expression of
recombinant proteins. J. Vis. Exp. doi: 10.3791/50521
Malpede, B. M., and Tolia, N. H. (2014). Malaria adhesins: structure and function.
Cell. Microbiol. 16, 621–631. doi: 10.1111/cmi.12276
Maskus, D. J., Bethke, S., Seidel, M., Kapelski, S., Addai-Mensah, O., Boes, A., et al.
(2015). Isolation, production and characterization of fully human monoclonal
antibodies directed to Plasmodium falciparum MSP10. Malar. J. 14, 276. doi:
10.1186/s12936-015-0797-x
Moorthy, V., and Hill, A. V. S. (2001). Malaria vaccines. Br. Med. Bull. 62, 59–72.
doi: 10.1093/bmb/62.1.59
Moorthy, V. S., Newman, R. D., and Okwo-Bele, J.-M. (2013). Malaria
vaccine technology roadmap. Lancet 382, 1700–1701. doi: 10.1016/S0140-
6736(13)62238-2
Moss, D. K., Remarque, E. J., Faber, B. W., Cavanagh, D. R., Arnot, D. E., Thomas,
A. W., et al. (2012). Plasmodium falciparum 19-kilodalton merozoite surface
protein 1 (MSP1)-specific antibodies that interfere with parasite growth in vitro
can inhibit MSP1 processing, merozoite invasion, and intracellular parasite
development. Infect. Immun. 80, 1280–1287. doi: 10.1128/IAI.05887-11
O’Donnell, R. A., de Koning-Ward, T. F., Burt, R. A., Bockarie, M., Reeder,
J. C., Cowman, A. F., et al. (2001). Antibodies against merozoite surface
protein (MSP)-1(19) are a major component of the invasion-inhibitory
response in individuals immune to malaria. J. Exp. Med. 193, 1403–1412. doi:
10.1084/jem.193.12.1403
Osier, F. H. A., Fegan, G., Polley, S. D., Murungi, L., Verra, F., Tetteh, K. K.
A., et al. (2008). Breadth and magnitude of antibody responses to multiple
Plasmodium falciparummerozoite antigens are associated with protection from
clinical malaria. Infect. Immun. 76, 2240–2248. doi: 10.1128/IAI.01585-07
Pasare, S., Wright, K., Campbell, R., Morris, W., Ducreux, L., Chapman, S.,
et al. (2013). The sub-cellular localisation of the potato (Solanum tuberosum
L.) carotenoid biosynthetic enzymes, CrtRb2 and PSY2. Protoplasma 250,
1381–1392. doi: 10.1007/s00709-013-0521-z
Penny, M. A., Galactionova, K., Tarantino, M., Tanner, M., and Smith, T.
A. (2015). The public health impact of malaria vaccine RTS,S in malaria
endemic Africa: country-specific predictions using 18 month follow-up Phase
III data and simulation models. BMC Med. 13:170. doi: 10.1186/s12916-015-
0408-2
Persson, K. E. M., McCallum, F. J., Reiling, L., Lister, N. A., Stubbs, J., Cowman,
A. F., et al. (2008). Variation in use of erythrocyte invasion pathways by
Plasmodium falciparum mediates evasion of human inhibitory antibodies.
J. Clin. Invest. 118, 342–351. doi: 10.1172/JCI32138
Rademacher, T., Sack, M., Arcalis, E., Stadlmann, J., Balzer, S., Altmann, F., et al.
(2008). Recombinant antibody 2G12 produced in maize endosperm efficiently
neutralizes HIV-1 and contains predominantly single-GlcNAc N-glycans. Plant
Biotechnol. J. 6, 189–201. doi: 10.1111/j.1467-7652.2007.00306.x
Reddy, S. B., Anders, R. F., Cross, N., Mueller, I., Senn, N., Stanisic, D. I., et al.
(2015). Differences in affinity of monoclonal and naturally acquired polyclonal
antibodies against Plasmodium falciparummerozoite antigens. BMCMicrobiol.
15:133. doi: 10.1186/s12866-015-0461-1
Richards, J. S., Arumugam, T. U., Reiling, L., Healer, J., Hodder, A. N., Fowkes,
F. J. I., et al. (2013). Identification and prioritization of merozoite antigens
as targets of protective human immunity to Plasmodium falciparum malaria
for vaccine and biomarker development. J. Immunol. 191, 795–809. doi:
10.4049/jimmunol.1300778
Rosenberg, Y. J., Walker, J., Jiang, X., Donahue, S., Robosky, J., Sack, M.,
et al. (2015). A highly stable minimally processed plant-derived recombinant
acetylcholinesterase for nerve agent detection in adverse conditions. Sci. Rep.
5:13247. doi: 10.1038/srep13247
Rosenberg, Y., Sack, M., Montefiori, D., Forthal, D., Mao, L., Hernandez-Abanto,
S., et al. (2013). Rapid high-level production of functional HIV broadly
neutralizing monoclonal antibodies in transient plant expression systems. PLoS
ONE 8:e58724. doi: 10.1371/journal.pone.0058724
RTS,S Clinical Trials Partnership (2015). Efficacy and safety of RTS,S/AS01malaria
vaccine with or without a booster dose in infants and children in Africa: final
results of a phase 3, individually randomised, controlled trial. Lancet 386,
31–45. doi: 10.1016/S0140-6736(15)60721-8
RTS,S Clinical Trials Partnership., Agnandji, S. T., Lell, B., Fernandes, J. F.,
Abossolo, B. P., Methogo, B. G. N. O., et al. (2012). A phase 3 trial of
Frontiers in Plant Science | www.frontiersin.org 14 December 2015 | Volume 6 | Article 1169
Spiegel et al. Transient Plant Expression-Based Vaccine Development
RTS,S/AS01malaria vaccine in African infants.N. Engl. J. Med. 367, 2284–2295.
doi: 10.1056/NEJMoa1208394
Sack, M., Rademacher, T., Spiegel, H., Boes, A., Hellwig, S., Drossard, J., et al.
(2015). From gene to harvest: insights into upstream process development for
the GMP production of a monoclonal antibody in transgenic tobacco plants.
Plant Biotechnol. J. 13, 1094–1105. doi: 10.1111/pbi.12438
Santi, L., Giritch, A., Roy, C. J., Marillonnet, S., Klimyuk, V., Gleba, Y., et al. (2006).
Protection conferred by recombinant Yersinia pestis antigens produced by a
rapid and highly scalable plant expression system. Proc. Natl. Acad. Sci. U.S.A.
103, 861–866. doi: 10.1073/pnas.0510014103
Sim, B. K. B., Narum, D. L. D., Liang, H. H., Fuhrmann, S. R. S., Obaldia, N. N.,
Gramzinski, R. R., et al. (2001). Induction of biologically active antibodies in
mice, rabbits, and monkeys by Plasmodium falciparum EBA-175 region II DNA
vaccine.Mol. Med. 7, 247–254.
Spiegel, H., Boes, A., Kastilan, R., Kapelski, S., Edgue, G., Beiss, V., et al. (2015). The
stage-specific in vitro efficacy of a malaria antigen cocktail provides valuable
insights into the development of effective multi-stage vaccines. Biotechnol. J.
10, 1651–1659. doi: 10.1002/biot.201500055
Starkevic, U., Bortesi, L., Virgailis, M., RuŽauskas, M., Giritch, A., and
RaŽanskienë, A. (2015). High-yield production of a functional bacteriophage
lysin with antipneumococcal activity using a plant virus-based expression
system. J. Biotechnol. 200, 10–16. doi: 10.1016/j.jbiotec.2015.02.028
Stowers, A. W. A., Kennedy, M. C. M., Keegan, B. P. B., Saul, A. A.,
Long, C. A. C., and Miller, L. H. L. (2002). Vaccination of monkeys with
recombinant Plasmodium falciparum apical membrane antigen 1 confers
protection against blood-stage malaria. Infect. Immun. 70, 6961–6967. doi:
10.1128/IAI.70.12.6961-6967.2002
Todryk, S. M., and Hill, A. V. S. (2007). Malaria vaccines: the stage we are at. Nat.
Rev. Microbiol. 5, 487–489. doi: 10.1038/nrmicro1712
Voepel, N., Boes, A., Edgue, G., Beiss, V., Kapelski, S., Reimann, A., et al.
(2014). Malaria vaccine candidate antigen targeting the pre-erythrocytic stage
of Plasmodium falciparum produced at high level in plants. Biotechnol. J. 9,
1435–1445. doi: 10.1002/biot.201400350
Wang, L., Black, C. G., Marshall, V. M., and Coppel, R. L. (1999). Structural and
antigenic properties of merozoite surface protein 4 of Plasmodium falciparum.
Infect. Immun. 67, 2193–2200.
Wilby, K. J., Lau, T. T. Y., Gilchrist, S. E., and Ensom, M. H. H. (2012). Mosquirix
(RTS,S): a novel vaccine for the prevention of Plasmodium falciparummalaria.
Ann. Pharmacother. 46, 384–393. doi: 10.1345/aph.1Q634
Wouters, M. A., Rigoutsos, I., Chu, C. K., Feng, L. L., Sparrow, D. B., and
Dunwoodie, S. L. (2005). Evolution of distinct EGF domains with specific
functions. Protein Sci. 14, 1091–1103. doi: 10.1110/ps.041207005
Conflict of Interest Statement: The authors declare that the research was
conducted in the absence of any commercial or financial relationships that could
be construed as a potential conflict of interest.
Copyright © 2015 Spiegel, Boes, Voepel, Beiss, Edgue, Rademacher, Sack, Schillberg,
Reimann and Fischer. This is an open-access article distributed under the terms
of the Creative Commons Attribution License (CC BY). The use, distribution or
reproduction in other forums is permitted, provided the original author(s) or licensor
are credited and that the original publication in this journal is cited, in accordance
with accepted academic practice. No use, distribution or reproduction is permitted
which does not comply with these terms.
Frontiers in Plant Science | www.frontiersin.org 15 December 2015 | Volume 6 | Article 1169
